Eli Lilly and Company (NYSE:LLY) Stock Price Up 2.4% – What’s Next?

Shares of Eli Lilly and Company (NYSE:LLY) were up 2.4% during mid-day trading on Tuesday . The stock traded as high as $997.52 and last traded at $990.1140. Approximately 2,967,129 shares were traded during mid-day trading, a decline of 8% from the average daily volume of 3,214,761 shares. The stock had previously closed at $966.99.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Media coverage highlighted Eli Lilly’s leadership in the GLP-1 market, saying its best-in-class drugs are helping it cement dominance in obesity and diabetes treatment. GLP-1 Wars: Winners & Losers
• Positive Sentiment: Barclays raised its price target on Lilly and kept an Overweight rating, reinforcing confidence in the company’s long-term earnings and pipeline outlook. Barclays Sees Reinforced Long-Term Growth Narrative for Eli Lilly and Company (LLY)
• Positive Sentiment: Lilly announced an additional $4.5 billion investment in U.S. manufacturing, which signals confidence in continued demand for its obesity drugs and supports future supply expansion. Eli Lilly (LLY) Invests Another $4.5 Billion in U.S. Manufacturing as Weight-Loss Drugs Takeoff
• Positive Sentiment: New phase 4 tirzepatide study activity in India suggests Lilly is still broadening the clinical and commercial reach of its key obesity franchise. Eli Lilly Extends Tirzepatide Push With New Phase 4 Study in India
• Positive Sentiment: Roche said its Alzheimer’s blood test with Eli Lilly cleared European approval, adding a potential future diagnostics-related upside for Lilly’s neuroscience efforts. Roche, Eli Lilly Alzheimer’s Blood Test Cleared In Europe For Earlier Detection
• Neutral Sentiment: Lilly’s 150th-anniversary charitable announcement is positive for brand image, but it is unlikely to move the stock materially on its own. In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries
• Neutral Sentiment: Reuters reported that Lilly paused an obesity awareness campaign in India after regulatory scrutiny, which creates some headline risk but does not appear to be a core business setback. Exclusive: Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity
• Negative Sentiment: Articles warning about pricing pressure and “sell in May” seasonality suggest some investors are worried Lilly’s valuation could be vulnerable if growth expectations cool. Lilly Bounces Into ‘Sell in May’ Territory as Pricing Pressures Loom

Analysts Set New Price Targets

Several equities analysts have recently issued reports on LLY shares. Barclays boosted their price target on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a report on Monday, May 4th. CICC Research boosted their price target on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a report on Wednesday, February 11th. Daiwa Securities Group boosted their price target on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Scotiabank reissued an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a report on Thursday, February 5th. Finally, Argus boosted their price objective on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,218.33.

Eli Lilly and Company Stock Up 2.4%

The firm’s 50-day simple moving average is $941.13 and its 200 day simple moving average is $993.05. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The stock has a market capitalization of $932.43 billion, a P/E ratio of 35.17, a PEG ratio of 1.03 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors and hedge funds have recently modified their holdings of the company. Chase Investment Counsel Corp bought a new stake in shares of Eli Lilly and Company in the 1st quarter valued at about $281,000. Phillip James Consulting Co. bought a new stake in shares of Eli Lilly and Company in the 1st quarter valued at about $190,000. Fortis Capital Management LLC raised its holdings in shares of Eli Lilly and Company by 1.3% in the 1st quarter. Fortis Capital Management LLC now owns 8,839 shares of the company’s stock valued at $8,130,000 after purchasing an additional 114 shares during the period. Meiji Yasuda America Inc raised its holdings in shares of Eli Lilly and Company by 2.8% in the 1st quarter. Meiji Yasuda America Inc now owns 11,072 shares of the company’s stock valued at $10,184,000 after purchasing an additional 304 shares during the period. Finally, Temasek Holdings Private Ltd raised its holdings in shares of Eli Lilly and Company by 47.0% in the 1st quarter. Temasek Holdings Private Ltd now owns 173,259 shares of the company’s stock valued at $159,358,000 after purchasing an additional 55,412 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.